Patent Applications with Amino Acid Claims

The applications listed below recite at least one amino acid sequence in the claims that has a high degree of similarity to an influenza peptide sequence. For each application, we show the sequences that are similar to or identical to an influenza sequence. Although most all of the applications recite multiple sequences in the published claims, there is generally only one or a few claims in prosecution. The last column shows the non-U.S. jurisdictions where related applications have been filed. No information is provided here regarding the status of these applications.

This set of applications was identified using blastp. The criteria for inclusion in this table is that the patent claim sequences were at least 80% identical to an influenza peptide sequence.

Of the 57 applications in the table below, 40 are assigned to corporations and 17 are assigned to non-profit organizations.

Application No.	Assignee	Title	Sequence IDs in Claims Similar to Influenza	Other Jurisdictions with Family Members
20050208066	Academia Sinica	Recombinant baculovirus and virus-like particle	10	-
20070224594	Arbor Vita Corporation	Detection of influenza virus	4	Australia, Canada, Europe
20030099670	Artemis Pharmaceuticals GMBH	Influenza viruses with enhanced transcriptional and replicational capacities	25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47	Australia, Europe, Japan
20070026009	Inventors: Samuel Bogoch et al.	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds	15	Australia, Brazil, Canada, China, Europe, Israel, Japan, Korea, New Zealand
20050059107	Comissariat A L'Energie Atomique	Method of selecting hla-dp4 ligands and the applications thereof	5	Australia, Canada, Europe, France
20020081680	Corixa Corp.	Compositions and methods for the therapy and diagnosis of prostate cancer	973	Austria, Australia, Brazil, Canada, China, Czech Republic, Germany, Denmark, Europe, Spain, United Kingdom, Hungary, Israel, Japan, Korea, Mexico, Norway, New Zealand, Poland, Russian Federation, Turkey, South Africa
20020192763	Corixa Corp.	Compositions and methods for the therapy and diagnosis of prostate cancer	973	Austria, Australia, Brazil, Canada, China, Czech Republic, Germany, Denmark, Europe, Spain, United Kingdom, Hungary, Israel, Japan, Korea, Mexico, Norway, New Zealand, Poland, Russian Federation, Turkey, Taiwan, South Africa
20070253981	Cornell Research Foundation	Canine Influenza Virus	2	World
20040180058	Curelab, Inc.	Vaccine compositions and methods	3, 4	Australia, Canada, Europe, Japan
20070048287	Cytos Biotechnology AG	Molecular antigen array	213	Australia, Brazil, Canada, China, Europe, Israel, Japan, Korea
20070286871	Diversa Corporation	Vaccines	6	Canada, United Kingdom, Norway
20040268442	Dow AgroSciences LLC	Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production	4	Australia, Brazil, Canada, China, Europe, Japan, Korea
20060222664	Dow AgroSciences LLC	Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production	4	Australia, Brazil, Canada, China, Europe, Japan, Korea
20070107086	Dow AgroSciences LLC	Preparation of vaccine master cell lines using recombinant plant suspension cultures	4	Argentina, World
20070275014	Fraunhofer U.S.A. Inc.	Influenza antigens, vaccine compositions, and related methods	1, 2, 3, 4, 7, 8, 11, 12, 13, 16, 18, 20, 24	Australia, Canada, China, Europe
20060188469	General Electric Company	Vaccine delivery compositions and methods of use	9	Austria, Australia, Canada, China, Germany, Europe, Spain, Japan, Korea
20040202673	Genesis Biotech, Inc.	Constructs of branched synthetic peptide immunogens with artificial T helper cell epitopes coupled to B cell epitopes	1	China
20050106563	Genesis Biotech, Inc.	Epitope profiles of SARS coronavirus	5, 6	-
20070042001	Hawaii Biotech, Inc.	Influenza recombinant subunit vaccine	1, 2, 3, 4, 5, 6, 7	World
20070042002	Hawaii Biotech, Inc.	Influenza recombinant subunit vaccine	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11	World
20080008725	Hawaii Biotech, Inc.	Influenza recombinant subunit vaccine	1, 2, 3, 4, 5, 6, 7, 8, 9, 10	World
20070092536	Heska Corporation	Cold-adapted equine influenza viruses	6, 9, 14, 22, 25, 28, 33, 37, 40, 43, 46, 49, 54, 62, 64, 67, 69, 72, 77, 85, 88, 96, 99, 101, 103, 105, 107, 109, 111, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan
20070172494	Heska Corporation	Cold-adapted equine influenza viruses	17, 24	Australia, Brazil, Canada, China, Germany, Europe, Spain, Japan, Korea
20070196388	Heska Corporation	Cold-adapted equine influenza viruses	2, 5, 8, 14, 17, 20, 24	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan
20040137015	The University of Pittsburgh	Cold-adapted equine influenza viruses	2, 5, 8, 11, 14, 17, 20, 24, 45, 48, 51, 55, 58, 63, 66, 69, 77, 81, 86, 89, 92, 95, 104, 107	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan
20030099634	IDM Pharma, Inc.	Compositions and methods for eliciting CTL immunity	99	Austria, Australia, Bulgaria, Brazil, Canada, China, Czech Republic, Germany, Denmark, Europe, Spain, Finland, Finland, Greece, Hungary, Hungary, Israel, Japan, Mexico, Norway, New Zealand, OAPI, Portugal, Russian Federation, Singapore, Slovakia, South Africa
20060293262	Immune Disease Institute, Inc.	Inhibition of gene expression using RNA interfering agents	28	Australia, Europe, Japan
20030108561	Innogenetics N.V.	Core-glycosylated HCV envelope proteins	82	ARIPO, Australia, Bulgaria, Brazil, Canada, China, Czech Republic, Europe, Croatia, Hungary, Israel, Japan, Mexico, New Zealand, Poland, Russian Federation, Slovakia, Yugoslavia, South Africa
20030152940	Innogenetics N.V.	Constructs and methods for expression of recombinant HCV envelope proteins	82	ARIPO, Australia, Bulgaria, Brazil, Canada, China, Czech Republic, Europe, Croatia, Hungary, Israel, Japan, Mexico, New Zealand, Poland, Russian Federation, Slovakia, Yugoslavia, South Africa
20080008683	Institut Gustave Rjoussy, Centre National de la Recherche Scientifique, and Universite Paris	Polypeptide Sequence Involved in the Modulation of the Immunosuppresive Effect of Viral Proteins	36, 72	Australia, Brazil, Canada, China, Europe, Japan
20070098742	Iowa State University Research Foundation	Canine influenza virus and related compositions and methods of use	2, 4, 6, 8, 10, 12, 14, 16	Argentina, World
20030219442	Kirin Beer	Human monoclonal antibodies to influenza M2 protein and methods of making and using same	1, 2, 3, 4, 5, 6, 7, 8	Australia, Canada, China, Europe, Japan
20050170334	Kirin Pharma Kabushiki Kaisha	Human monoclonal antibodies to influenza M2 protein and methods of making and using same	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24	Australia, Canada, China, Europe, Japan
20050042229	MedImmune Vaccines, Inc.	Influenza hemagglutinin and neuraminidase variants	35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68	Canada, Europe
20060008473	MedImmune Vaccines, Inc.	Influenza hemagglutinin and neuraminidase variants	11, 12, 13, 14, 15, 16, 17, 18, 19, 20	Australia, Canada, Europe, Japan
20070160622	MediVas	Method for assembling a polymer-biologic delivery composition	11, 12, 13, 14, 16	Austria, Australia, Canada, China, Germany, Europe, Spain, Japan, Korea
20040223976	Merck & Co. Inc	Influenza virus vaccine	1, 2, 10, 39, 59, 60, 61, 62, 126, 127, 128, 129, 130, 131, 132, 133, 1, 135, 136, 137, 138, 139, 143, 144, 145, 146, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168	Australia, Brazil, Canada, China, Europe, Japan, Korea, Mexico, Norway, Russian Federation, South Africa
20060018903	Merck Patent GMBH	TNF alpha-binding polypeptide compositions and methods	21	Brazil, Canada, China, Europe, Hungary, Japan, Korea, Mexico, Poland, Russian Federation, South Africa
20080003203	National Tsing Hua University	Pseudotyped baculovirus to stimulate immunogenicity against avian influenza	1	-
20070184526	Novavax, Inc.	Functional influenza virus like particles (VLPs)	43	Australia, Brazil, Canada, China, Europe, Japan, Korea, Mexico, Russian Federation, Singapore
20030175285	PF Medicament	Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid	189, 527, 529	Australia, Brazil, Canada, China, Europe, France, Japan, Mexico, South Africa
20080032921	Pharmexa Inc.	Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions	5, 6, 7, 8, 186	-
20050234222	Photobiotics Ltd.	Conjugate	6	Canada, Europe, United Kingdom, Japan
20040006022	President and Fellows of Harvard College	Synthetic peptides and methods of use for autoimmune disease therapies	1	Australia, Canada, Europe, Hungary, Israel, Japan, Norway, New Zealand, South Africa
20020165176	Powerject Vaccines	Nucleic acid immunization	1, 2, 3	Australia, Europe
20070066534	Queensland Institute	Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes	1, 5, 7, 18, 107, 108, 111, 112	Australia, Brazil, Canada, China, Europe, Japan, Korea
20070160631	Queensland Institute	Novel immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitopes	1, 3, 4	Australia, Brazil, Canada, China, Europe, Japan, Korea
20060222657	The Regents of the University of California	Polypeptide transduction and fusogenic peptides	2, 3	Australia, Canada, Europe
20050191318	Research Development Foundation	DNA immunocontraceptive vaccines and uses thereof	15	-
20030148928	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acid peptide conjugates	19	Australia
20030157118	Smithkline Beecham Biologicals	Tumour-specific animal proteins	10	Australia, Brazil, Canada, China, Czech Republic, Europe, United Kingdom, Hungary, Israel, Japan, Mexico, Norway, New Zealand, Poland, South Africa
20060280754	Tulane Educational Fund	Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in RNA viruses having class i membrane fusogenic envelope proteins	4	Australia, Brazil, Canada, Europe, Japan
20050074813	U.S. Army	Model for testing immunogenicity of peptides	1	ARIPO, Australia, Brazil, Canada, China, Europe, Japan, New Zealand
20060024670	Vical Inc.	Influenza virus vaccine composition and methods of use	76, 78	Australia, Canada, Europe, Japan
20060153871	Wisconsin Alumni Research Foundation	H3 equine influenza A virus	1, 2, 3, 4, 5, 6, 7, 8, 17, 18	-
20070059806	Yeda Research and Development	Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection	1, 13, 14, 15	Australia, Canada, Europe, Japan, Korea, Mexico, New Zealand, Poland, Russian Federation, South Africa
20070122424	Yeda Research and Development	Peptide-Based Vaccine for Influenza	1, 2, 3, 4, 5	Australia, Brazil, Canada, Europe, Israel, Japan, New Zealand

The information contained in this page was believed to be correct at the time it was collated. New patents and patent applications, altered status of patents, and case law may have resulted in changes in the landscape. CAMBIA makes no warranty that it is correct or up to date at this time and accepts no liability for any use that might be made of it. Corrections or updates to the information are welcome. Please send an email to info@bios.net.

Comments (0)

Previous Next

CAMBIA Login